BioTuesdays

Tag - Jason Kolbert

ADMA Biologics Logo
Markets

Dawson James removes PT for ADMA Biologics

Dawson James Securities removed its prior $4 price target for ADMA Biologics (NASDAQ:ADMA) after the company reported third quarter financial results. The stock was changing hands at $4.09 in afternoon trading on Dec. 5...

December 5, 2019
Check Cap
Markets

Dawson James starts Check Cap at buy; PT $4

Dawson James Securities initiated coverage of Check Cap (NASDAQ:CHEK) with a “buy” rating and $4 price target. The stock closed at $1.39 on Dec. 4. The company has developed an imaging technology’ known as C-Scan, using...

December 5, 2019
Adamis Pharma
Markets

Dawson James cuts Adamis Pharma PT to $1 from $4

Dawson James reduced its price target for Adamis Pharmaceuticals (NASDAQ:ADMP) to $1 from $4 on the heels of an FDA complete response letter (CRL) for the company’s high-dose naloxone injection product for the treatment...

November 26, 2019
Dyadic
Markets

Dawson James starts Dyadic at buy; PT $14

Dawson James Securities launched coverage of Dyadic International (NASDAQ:DYAI) with a “buy” rating and $14 price target. The stock closed at $6.66 on Oct. 15. Dyadic has been developing a gene expression platform over...

October 16, 2019
Markets

Dawson James starts Fortress Biotech at buy; PT $19

Dawson James Securities launched coverage of Fortress Biotech (NASDAQ:FBIO) with a “buy” rating and price target of $19. The stock closed at $6.51 on Aug. 23. “Creating a launch pad for biotechnology assets, Fortress...

August 26, 2019
Athersys Logo
Markets

Dawson James starts Athersys at buy; PT $11

Dawson James Securities launched coverage of Athersys (NASDAQ:ATHX) with a “buy” rating and $11 price target. The stock closed at $1.40 on Aug. 23. “Athersys has the potential to change the treatment paradigm for...

August 26, 2019
Anavex
Developments

Dawson James starts Anavex at buy: PT $16

Dawson James initiated coverage of Anavex Life Sciences (NASDAQ:AVXL) with a “buy” rating and $16 price target. The stock closed $2.54 on July 23. Anavex is pioneering a new treatment in CNS diseases like...

July 24, 2019
Citius Logo
Markets

HCW starts Citius Pharma at buy; PT $11

H.C. Wainwright initiated coverage of Citius Pharmaceuticals (NASDAQ:CTXR) with a “buy” rating and price target of $11. The stock finished at $2.40 on May 22. The company’s antibiotic lock therapy drug combination, Mino...

May 23, 2018
Can-Fite
Markets

Maxim cuts Can-Fite Biopharma to hold; removes PT

Maxim Group downgraded Can-Fite Biopharma (NYSE American:CANF) to “hold” from “buy” and removed its previous $7 price target after the company announced a $5-million registered direct offering. The stock was quoted at...

March 9, 2018